You have 4 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FWD1509 MsOH in advanced non-small cell lung cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Canton, Houston (FWD1509 MsOH)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • FWD1509 MsOH
  • Canton, Ohio
  • +1 more
Jul 20, 2022

Metabolic Response to Food in Advanced Lung Cancer

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Weight loss (%)
  • (no location specified)
Jun 30, 2023

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy

Not yet recruiting
  • Non-small Cell Lung Cancer Metastatic
    • (no location specified)
    Sep 13, 2023

    NSCLC Trial in Guangzhou (BL-M07D1)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Nov 1, 2023

    Untreated Advanced NSCLC Trial in Fuzhou (Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and

    Recruiting
    • Untreated Advanced Non-small Cell Lung Cancer
    • Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
    • Fuzhou, Fujian, China
      Fujian Cancer Hospital
    Nov 13, 2023

    Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

    Recruiting
    • Nonsmall Cell Lung Cancer
    • HS-10365 capsules
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 22, 2023

    NSCLC Trial in Shanghai (SI-B001, SI-B003)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Jul 10, 2023

    NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

    Not yet recruiting
    • NSCLC
    • Non-small Cell Lung Cancer
    • Apatinib + Fluzoparib
    • Apatinib + Fluzoparib + Adebrelimab
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 27, 2023

    Non-Small-Cell Lung Cancer Trial in Guangzhou (PLB1004)

    Recruiting
    • Non-Small-Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong General Hospital
    Aug 25, 2023

    ALK Positive NSCLC Trial in Guangzhou (Loratinib)

    Recruiting
    • ALK Positive Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial Perople's Hospital
    Oct 19, 2023

    Advanced Non-small-cell Lung Cancer Trial in Shanghai (AK112, AK104, caboplatin)

    Not yet recruiting
    • Advanced Non-small-cell Lung Cancer
    • Shanghai, China
      Shanghai Pulmonary Hospital
    Jun 6, 2023

    Locally Advanced or Metastatic NSCLC Trial (HB1801, Taxotere)

    Not yet recruiting
    • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    • (no location specified)
    May 8, 2023

    NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Tislelizumab IV
    • +2 more
    • (no location specified)
    Oct 25, 2023

    Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III Trial in Tampa (Genomically

    Recruiting
    • Nonsmall Cell Lung Cancer
    • +3 more
    • Genomically Guided Radiation Therapy (RT)
    • Tampa, Florida
      Moffitt Cancer Center
    May 23, 2023

    NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100

    Not yet recruiting
    • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
    • MCLA-129: 1500mg or 2000mg IV Q2W
    • Befotertinib: 75 mg or 100 mg Po QD
    • Bengbu, Anhui, China
    • +2 more
    Aug 28, 2023

    Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

    Not yet recruiting
    • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    • New York, New York
      NYU Langone Health
    Apr 4, 2023

    Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

    Not yet recruiting
    • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    • New York, New York
      NYU Langone Health
    Apr 4, 2023

    Local Advanced NSCLC Trial (Toripalimab, Radical thoracic radiotherapy)

    Not yet recruiting
    • Local Advanced Non-small Cell Lung Cancer
    • (no location specified)
    Jun 2, 2023

    Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)

    Not yet recruiting
    • Advanced Squamous Non-Small-Cell Lung Cancer
    • (no location specified)
    Jun 11, 2023

    NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Fairfax, Virginia
      NEXT Virginia
    Sep 18, 2023

    Carcinoma, Non-Small Cell Lung Trial in Zhengzhou (BAI combine with DEB-BACE)

    Not yet recruiting
    • Carcinoma, Non-Small Cell Lung
    • BAI combine with DEB-BACE
    • Zhengzhou, Henan, China
      Gang Wu
    Nov 7, 2023

    Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy Trial in Wuhan (CTV omitted or delineated)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • CTV omitted or delineated
    • Wuhan, Hubei, China
      Hubei Cancer Hospital
    Sep 1, 2023

    NSCLC Trial in Guangzhou (SKB264, Pembrolizumab, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University, Cancer Center
    Apr 14, 2023

    NSCLC Trial in Shanghai (BL-M02D1)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Jul 10, 2023

    Non Small Cell Lung Cancer Trial (TGRX-326, Crizotinib)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • (no location specified)
    Oct 8, 2023